Back

Optimal anticoagulation strategy for left ventricular assist device patients undergoing thoracentesis: a retrospective study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Devices in heart failure: new findings Ventricular Assist Devices ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Sharana Hegde

Sanger Heart and Vascular Institute, Charlotte (United States of America)

7 More presentations in this session

Presentation thumbnail
Predictors of Right vEntricular Failure aftER LVAD implantation: PREFER LVAD study
Associate Professor M. Cameli (Siena, IT)
Abstract Slides Video
Presentation thumbnail
Elevated cancer biomarkers in patients with severe heart failure could be a potential predictor of mortality during LVAD support
Doctor A. Bielka (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
Right ventricular failure following left ventricular assist device implantation.
Associate Professor M. Laimoud (Riyadh, SA)
Abstract Slides Video
Presentation thumbnail
A meta-analysis of the efficacy and safety of exercise-based cardiac rehabilitation in patients with left ventricular assist devices.
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Impact of digoxin on gastrointestinal bleeding following left ventricular assist device implantation: a systematic review and meta-analysis
Doctor H. Alani (Doha, QA)
Abstract Slides Video

Access the full session

Session thumbnail
Devices in heart failure: new findings

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Impact of delayed heparin bridging on bleeding and stroke after heartmate 3 left ventricular assist device implantation
thumbnail
Congress Presentation
Efficacy and safety of antithrombotic regimens in patients with durable left ventricular assist devices: a systematic review and bayesian network meta-analysis
thumbnail
Congress Presentation
Dual or single anticoagulation/antiplatelet therapy in LVAD patients?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources